{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:44:09Z","timestamp":1789602249554,"version":"build-2803163510"},"reference-count":11,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Zanubrutinib is a next\u2010generation selective Bruton's tyrosine kinase inhibitor (BTKi) with superior efficacy and lower cardiotoxicity rates seen in clinical trials over first\u2010generation ibrutinib in CLL\/SLL patients. We present real\u2010world treatment patterns based on a practice change from ibrutinib to zanubrutinib in CLL\/SLL patients in an integrated community oncology practice. We retrospectively analyzed adult patients who filled at least 3\u2009months of zanubrutinib at Kaiser Permanente Northern California. Treatment patterns, adverse events (AE), and mortality were reported. Two hundred eighty\u2010one patients received zanubrutinib; 190 patients switched from ibrutinib. Similar AE rates were seen with both BTKis, with a lower proportion of patients with treatment\u2010limiting AEs and lower cardiac AE rates with zanubrutinib. Most patients remained on zanubrutinib at the end of data collection without treatment\u2010related deaths reported. In the real\u2010world setting, zanubrutinib is effective and safe in patients with or without prior ibrutinib use, with low cardiotoxicity and AE rates, though data was limited by a difference in follow\u2010up time.<\/jats:p>","DOI":"10.1002\/cam4.71300","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:26:58Z","timestamp":1760534818000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real\u2010World Treatment Patterns and Outcomes of Zanubrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (\n                    <scp>CLL<\/scp>\n                    \/\n                    <scp>SLL<\/scp>\n                    )"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8151-9784","authenticated-orcid":false,"given":"Margaret Li","family":"Krackeler","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology Kaiser Permanente San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant H.","family":"Chee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Kaiser Permanente San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur K.","family":"Orchanian","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Kaiser Permanente San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Kaiser Permanente San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-8212","authenticated-orcid":false,"given":"Lisa","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Kaiser Permanente Roseville  Roseville California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Research Kaiser Permanente Northern California  Pleasanton California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Research Kaiser Permanente Northern California  Pleasanton California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori C.","family":"Sakoda","sequence":"additional","affiliation":[{"name":"Division of Research Kaiser Permanente Northern California  Pleasanton California USA"},{"name":"Department of Health Systems Science Kaiser Permanente Bernard J. Tyson School of Medicine  Pasadena California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Buchanan","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd  San Carlos California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Massoudi","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd  San Carlos California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Kaiser Permanente San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahan","family":"Tavakoli","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Kaiser Permanente San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"e_1_2_1_8_2_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687"},{"key":"e_1_2_1_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_2_1_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_2_1_8_5_1","unstructured":"P.Hillmen B.Eichhorst J. R.Brown et\u00a0al. \u201cResults of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma \u201dAbstract LB1900. EHA 2021 Virtual Congress. Presented June 11 2021."},{"key":"e_1_2_1_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e19506"},{"key":"e_1_2_1_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174289"},{"key":"e_1_2_1_8_8_1","unstructured":"M.Shadman T.Munir T.Robak et\u00a0al. \u201cZanubrutinib vs Bendamustine + Rituximab in Patients With Treatment\u2010Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Extended Follow\u2010Up of the SEQUOIA Study \u201dAbstract 154.17th International Conference on Malignant Lymphoma; Lugano Switzerland. Presented June 13\u201317 2023."},{"key":"e_1_2_1_8_9_1","unstructured":"\u201cFDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma \u201dhttps:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010zanubrutinib\u2010chronic\u2010lymphocytic\u2010leukemia\u2010or\u2010small\u2010lymphocytic\u2010lymphoma. News Release FDA 2023."},{"key":"e_1_2_1_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00377"},{"key":"e_1_2_1_8_11_1","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/22.172"},{"key":"e_1_2_1_8_12_1","doi-asserted-by":"crossref","unstructured":"J. Z.Hou S.Blanc G. A.Maglinte et\u00a0al. \u201cReal\u2010World Bruton Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in US Community Oncology Practices \u201dAbstract P685. 2024 EHA Congress; Madrid Spain. Presented June 13\u201316 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.e19020"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:25:54Z","timestamp":1761809154000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":11,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/cam4.71300"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71300","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71300"}}